Skip to main content
Top
Published in: Familial Cancer 1/2007

01-03-2007 | Original Paper

Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred

Authors: Florian D. Vogl, Mike D. Badzioch, Linda Steele, Susan L. Neuhausen, David E. Goldgar

Published in: Familial Cancer | Issue 1/2007

Login to get access

Abstract

Objective

Germline mutations in the BRCA1 gene are associated with an increased risk of breast and ovarian cancer, but there is controversy about the true magnitude of these risks. Observed differences can arise from several sources, both genetic and methodological. To examine the efficiency and bias associated with different methods of risk calculation, we analyzed a single mutation in a large pedigree with known ascertainment.

Methods

Age-specific penetrance of breast and ovarian cancer was estimated using the Kaplan–Meier method and two likelihood-based approaches [maximum likelihood estimation, maximization of the logarithm of the odds (LOD) score]. Excess risk of other cancers due to the BRCA1 mutation was assessed.

Results

The estimated risk of breast and ovarian cancer at age 70 was 0.80 using the Kaplan–Meier approach and 0.55 using the maximum likelihood method. Both likelihood-based methods yielded similar results for the combined breast/ovarian phenotype, but using the maximum LOD score method lower estimates were obtained if only cancer at one site was considered. In the examined family, a high risk of ovarian cancer was found which might be an effect of the central location of the mutation within BRCA1. The risk of cancer at other sites than breast and ovaries was significantly elevated, but it was not possible to identify a single cancer site that could be said to be associated with the BRCA1 mutation.

Conclusion

Estimating the penetrance of a specific mutation using different approaches, we found that both the choice of study population and statistical method affect the magnitude of the estimates.
Literature
1.
go back to reference Goldgar DE, Fields P, Lewis CM et al (1994) A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis. J Natl Cancer Inst 86:200–209PubMedCrossRef Goldgar DE, Fields P, Lewis CM et al (1994) A large kindred with 17q-linked breast and ovarian cancer: genetic, phenotypic, and genealogical analysis. J Natl Cancer Inst 86:200–209PubMedCrossRef
2.
go back to reference Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265–271 Easton DF, Ford D, Bishop DT (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265–271
3.
go back to reference Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692–695 Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343:692–695
4.
go back to reference Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRef Struewing JP, Hartge P, Wacholder S et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408PubMedCrossRef
5.
go back to reference Hopper JL, Southey MC, Dite GS et al (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 8:741–747PubMed Hopper JL, Southey MC, Dite GS et al (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 8:741–747PubMed
6.
go back to reference Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedCrossRef Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72:1117–1130PubMedCrossRef
7.
go back to reference Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRef Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRef
8.
go back to reference Botkin JR, Croyle RT, Smith KR et al (1996) A model protocol for evaluating the behavioral and psychosocial effects of BRCA1 testing. J Natl Cancer Inst 88:872–882PubMedCrossRef Botkin JR, Croyle RT, Smith KR et al (1996) A model protocol for evaluating the behavioral and psychosocial effects of BRCA1 testing. J Natl Cancer Inst 88:872–882PubMedCrossRef
9.
go back to reference StataCorp (1999) Stata statistical software [release 6.0]. Stata Corporation, College Station, TX StataCorp (1999) Stata statistical software [release 6.0]. Stata Corporation, College Station, TX
10.
go back to reference Hasstedt SJ, Cartwright PE (1989) Pedigree analysis package. University of Utah, Salt Lake City, UT Hasstedt SJ, Cartwright PE (1989) Pedigree analysis package. University of Utah, Salt Lake City, UT
11.
go back to reference Hodge SE, Elston RC (1994) Lods, wrods, and mods: the interpretation of lod scores calculated under different models. Genet Epidemiol 11:329–342PubMedCrossRef Hodge SE, Elston RC (1994) Lods, wrods, and mods: the interpretation of lod scores calculated under different models. Genet Epidemiol 11:329–342PubMedCrossRef
12.
go back to reference Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (eds) (1997) Cancer incidence in five continents, vol VII. IARC Scientific Pub No 143. IARC, Lyon, Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (eds) (1997) Cancer incidence in five continents, vol VII. IARC Scientific Pub No 143. IARC, Lyon,
13.
go back to reference Cannings C, Thompson EA (1977) Ascertainment in the sequential sampling of pedigrees. Clin Genet 12:208–212PubMedCrossRef Cannings C, Thompson EA (1977) Ascertainment in the sequential sampling of pedigrees. Clin Genet 12:208–212PubMedCrossRef
14.
go back to reference Begg CB (2002) On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 94:1221–1226PubMed Begg CB (2002) On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 94:1221–1226PubMed
15.
go back to reference Thompson D, Easton D (2002) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329–336PubMed Thompson D, Easton D (2002) Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329–336PubMed
16.
go back to reference Langston AA, Stanford JL, Wicklund KG, Thompson JD, Blazej RG, Ostrander EA (1996) Germ-line BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet 58:881–884PubMed Langston AA, Stanford JL, Wicklund KG, Thompson JD, Blazej RG, Ostrander EA (1996) Germ-line BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet 58:881–884PubMed
17.
go back to reference Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365PubMed Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358–1365PubMed
18.
go back to reference Chen-Shtoyerman R, Figer A, Fidder HH et al (2001) The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients. Br J Cancer 84:475–477PubMedCrossRef Chen-Shtoyerman R, Figer A, Fidder HH et al (2001) The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients. Br J Cancer 84:475–477PubMedCrossRef
Metadata
Title
Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred
Authors
Florian D. Vogl
Mike D. Badzioch
Linda Steele
Susan L. Neuhausen
David E. Goldgar
Publication date
01-03-2007
Publisher
Kluwer Academic Publishers
Published in
Familial Cancer / Issue 1/2007
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-006-9106-8

Other articles of this Issue 1/2007

Familial Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine